What Happened?
Cambridge, MA-based STIMIT Appointed Michael Goldberg as Chief Executive Officer
About the Company
STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
About the Person
Michael Goldberg is Chief Executive Officer at STIMIT. Previously, Michael held various senior HR leadership roles in the industry.
Info Source
News
Short Profile